Bio-Techne Officer Steven Crouse Stock Transactions and Holdings Update

This Form 4 filing reports transactions by Steven C. Crouse, President of Diagnostic & Spatial Biology at Bio-Techne Corp (TECH), on June 2, 2026. Crouse acquired 600 shares of common stock through the vesting of restricted stock units (RSUs) at $0 cost, while simultaneously selling 216 shares at $49.77 per share. The filing also corrects a mathematical error from a previous filing, increasing his beneficial ownership by 40 shares. The filing details Crouse's extensive equity holdings, including 12,436 RSUs with various vesting schedules through 2029, and stock options for 117,140 shares with exercise prices ranging from $48.61 to $120.46 and expiration dates through 2036. The transactions resulted in Crouse holding 6,761 shares of common stock directly following the transactions, plus substantial unvested equity awards. The filing is signed by Andrew Nick as attorney-in-fact for Crouse, indicating proper authorization for the reporting.